ABSTRACT. Theophylline is administered to preterm infants with pulmonary disease to improve pulmonary function and reduce apneic episodes. Because it potentially mediates both a-and B-receptor-effector mechanisms, we tested the hypothesis that it increases lipolysis, gluconeogenesis from glycerol, and energy expenditure in 16 preterm infants, eight of whom were treated therapeutically with theophylline for apnea of prematurity (T) and eight of whom were controls (C). Mean f SD postnatal ages were 4.8 f 1.9 wk (T) and 2.4 f 0.9 wk (C) ( p < 0.01).
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Theophylline is a xanthine derivative bronchodilator administered in neonatal intensive care units to the majority of premature infants with apnea and/or respiratory disease. Its pharmacologic effects include relaxation of the bronchial smooth muscle (I), stimulation of the hypoxic ventilatory drive, increased minute ventilation, increased diaphragmatic contractility (2) , decreased end-tidal Pcoz (I), and a reduced requirement for mechanical ventilation. It has several metabolic effects that could potentially mediate fuel kinetics, energy storage, and growth in preterm infants, including stimulating thermogenesis (3), increasing plasma glucose concentration (4), and augmenting lipolysis (5) with concomitant increases in circulating FFA concentrations and in FFA oxidation (3, (5) (6) (7) (8) .
In vitro, theophylline inhibits cAMP phosphodiesterase and increases intracellular cAMP and fuel mobilization (9). This mechanism, however, requires 300 pM theophylline (9, which is three to ten times concentrations maintained clinically. Furthermore, therapeutic doses of theophylline increased diaphragmatic contractility without increasing intracellular concentrations of cAMP in rats (2) .
Therapeutic doses (5-6 pg/mL, approximately 30 pM) increase plasma norepinephrine (3) and/or epinephrine (7). Toxic doses to canines produced hypokalemia, hypophosphatemia, hyperglycemia, and increased concentrations of epinephrine and norepinephrine (10, 11). These observations and the fact that the effects in canines were prevented or reversed by propranolol(l0, 12) imply mediation by P-adrenergic receptor-effector mechanisms.
Theophylline also is an adenosine receptor antagonist. Peters et al. (5) recently reported that theophylline (30 pM) increased lipolysis during fasting. These effects occurred without concomitant increases in circulating catecholamine concentrations, plasma glucose, insulin, or growth hormone.
In preterm infants, theophylline increased energy expenditure without altering respiratory exchange ratios (13), suggesting that the increased rate of energy expenditure was unaccompanied by alterations in the ratios of substrates oxidized to meet increased fuel requirements. However, it is also known that lipolysis can increase without detectable alterations in fuel oxidation ratios (14) . Alterations in the kinetics of fuel mobilization secondary to therapeutic doses of theophylline have not been measured in preterm infants, but may be of potential physiologic and clinical importance because the preterm infant's fat and energy reserves are less developed than those of term infants and are more difficult to achieve and maintain. Mechanisms that regulate fatty acid transport are intact in newborn term infants (15). Thus, increases in lipolytic rates by theophylline could generate increased fuel supplies for oxidation. Because similar data are lacking for the preterm infant, we tested the hypothesis that rates of lipolysis, hepatic glucose production, gluconeogenesis (from glycerol), and energy expenditure are increased secondary to treatment with theophylline for apnea of prematurity in preterm infants at 2 to 7 wk of postnatal life.
MATERIALS A N D METHODS
Subjects. Sixteen appropriate for gestational age preterm infants were recruited from the neonatal intensive care unit and assigned to either the theophylline treatment group or to the control group according to whether or not they were medicated with theophylline for apnea of prematurity, which was the only entry criterion distinguishing the two groups. Control infants were free of apnea during the study. Decisions to prescribe theophylline for symptoms of apnea were made independently from the study by a nonparticipating physician. Apnea was defined as cessation of breathing for 215 to 20 s, detected by chest plethysmography and bradycardia (<lo0 beatslmin). Known causes of apnea apart from prematurity had been ruled out. Theophylline was administered as an oral solution, 80 mg/ 15 mL (Roxane Laboratories, Inc., Columbus, OH) at doses of 2 to 4 mg/kg every 8 h with feedings throughout the study. Doses per kg body weight were maintained during the study. At entry, all infants had an estimated gestational age by Dubowitz score of 27 to 32 wk, were between 1.5 and 2 kg in body weight, were fed enterally 2100 kcal/kg/d, were clinically stable, breathing room air, without evidence of infection, and were not receiving steroid or diuretic medications. Infants were kept either in servocontrolled isolettes set to a skin temperature of 36.2 to 36.5"C or in open-air cribs. Infants in open-air cribs had stable body temperatures for at least 48 h before the study. All infants were fed every 3 to 4 h with Similac (Ross Laboratories, Columbus, OH) or Enfamil Preterm Formula 20 or 24 (Mead-Johnson, Evansville, IN) and had been gaining weight consistently for at least 3 d before the study (range, 8-25 g/kg/d). Eight infants treated with theophylline and eight control infants completed the study. 2H2180 data are unavailable for one theophyllinetreated infant and two control infants because baseline or postdose urine samples were not obtained. Two other infants did not complete the infusion protocol.
The protocol was approved by the Washington University School of Medicine Human Studies Committee, and signed informed consents were obtained from the parents of all infants.
Study protocol. The studies were performed in the neonatal intensive care unit (St. Louis Children's Hospital, Washington University, St. Louis, MO) or in the special care nursery (Barnes Hospital, Washington University) during 7 continuous d. Body water was measured on d 1 ; energy expenditure was measured between d 1 and 7; and lipolysis, glucose production, and the glycogenic contribution from glycerol were measured on d 7 as described below.
On d 1, 3 h after the previous feeding and after a urine sample for measurement of natural isotopic abundances was obtained, an accurately weighed solution that delivered approximately 0.2 g Q20/kg body weight (as 99.9 atom % 2H, MSD Isotopes, St. Louis, MO) and 0.45 g H2I80/kg body weight (as 10 or 15 atom % "0, Cambridge Isotope Laboratories, Woburn, MA) was administered orally or nasogastrically. Urine samples were obtained daily from d 1 to 7 in all infants, kept frozen at -20"C, and used to measure isotope dilution spaces and isotope elimination rates from which body water volume, C02 production, and energy expenditure were calculated according to the doubly labeled water method (16, 17). To minimize inaccuracies in calculated isotope elimination rates (18), each infant's formula was taken from a single lot.
On d 7, [2-'3C]glycerol (99 atom % 13C, MSD Isotopes) and [6,6-'H2]glucose (98.6 atom % 2H, MSD Isotopes) were infused to measure rates of hepatic glucose production, lipolysis, and gluconeogenesis from glycerol. To prepare the infusate materials, the tracers were mixed with 0.5 N saline, passed through 0.22-pm Millipore filters (Millipore Products, Bedford, MA), and stored in single-use septum-sealed vials for subsequent infusion and measurement of glycerol and glucose kinetics. The infusate was pyrogen-free, as shown by standard rabbit body temperature measurements after i.v. administration in a licensed commercial laboratory according to federal guidelines. In preparation for the tracer infusions in the infants, a needle was inserted into a peripheral vein 2 h after a feeding, and 1 h before the start of the infusion, except in one theophylline-treated infant, discussed below. The i.v. line was kept patent by infusing normal saline at 5 mL/h. Heparin was not used for this purpose. Sixty rnin after inserting the needle, the heel was warmed for a minimum of 5 min and a baseline blood sample of 0.5 to 0.6 mL was obtained by heel stick for determination of theophylline concentration, glucose concentration, and the natural abundance of I3C in glucose and glycerol. The isotopes were infused continuously by means of a calibrated Harvard syringe pump (Harvard Apparatus Co., Inc., So. Natick, MA) starting 175 + 27 min after the previous feeding (range, 170-200 min) for 180 min. In one theophylline-treated infant, the i.v. line was inserted at the completion of a feeding, and the infusion was started at 85 rnin from the previous feeding. In all infants, the average rate of glycerol infusion was 0.32 + 0.02 pmol/kg/min, and the glucose was infused at an average rate of 0.22 k 0.01 pmol/kg/min. Exact infusion rates for each infant were determined from the calibrated pump rates and the measured isotope concentrations in the infusate material. Blood samples (0.3-0.4 mL each) were drawn at 20-min intervals beginning 60 rnin after the start of the isotopic infusions; the serum was separated and frozen at -80°C. The total amount of blood drawn did not exceed 5% of the estimated blood volume (85 mL/kg). Infants remained in their isolettes, usually asleep. Infants were not fed during the infusion study; blood sugar levels were monitored periodically at the bedside to confirm normoglycemia. [1,1,2,3,3-2H5]glycerol (Tracer Technologies, Somerville, MA) was added to plasma samples as an internal standard for measurement of glycerol concentrations, as described below.
For measurement of theophylline concentrations, plasma was drawn between 7 and 8 h after theophylline administration on various days during the study. All children had theophylline measured on the day of the infusion study. Theophylline was measured from one to three additional times between the first and last days of the study according to whether blood was needed for clinical determinations. Theophylline concentrations were measured in the clinical laboratory using the Kodak Ektachem method (19). Caloric intake was determined from formula composition and volumes consumed.
Analytical Methods. Isotope ratio mass spectrometric analysis of 2H and '*0. For measurement of 2H enrichment, 5 pL of urine or of the dose water or standards were cryogenically distilled into reaction vials containing 100 mg of zinc (Friends of Biogeochemistry, Indiana University Foundation, Bloomington, IN). The vials were then heated to 600°C and kept isothermal for 5 min. For measurement of "0 enrichment, 1 mL of urine or of the dose water or standards was equilibrated with C 0 2 at 25°C for 24 h. Isotopic ratios in hydrogen gas and in C 0 2 were measured using a dual-inlet mass spectrometer (VG Sira Series 11), using hydrogen gas or C 0 2 calibrated against standard mean ocean water obtained from the National Bureau of Standards. The precision, estimated from the coefficient of variation from repeated analyses of calibration standards, was <I % for ''0, <4% for unenriched 'H, and 1 % for samples enriched with 'H.
Mass spectrometric analysis of glycerol and glucose. 2H and I3C abundance in glucose and glycerol was measured by standard GCMS methods (15, 20, 21). One hundred pL of plasma were combined with 10 nmol of [1,1,2,3,3 2H5]glycerol internal standard for measurement of plasma glycerol concentrations. Samples were chilled and 0.4 mL of Ba(OHi2 and 0.4 mL of ZnS04 were added to precipitate the proteins. Samples were centrifuged at 6000 rpm for 10 rnin at O°C, the supernatant was decanted, and the liquid was evaporated under nitrogen. The pentaacetate derivative of glucose and the triacetate derivative of glycerol were prepared by adding 40 pL of a 1:l volume mixture of acetic anhydride and pyridine to the dried eluates. The reaction mixtures were incubated at room temperature for 12 to 15 h. Selected ion monitoring GCMS of the glycerol and glucose molecular ion clusters (mjz 159, 160, 164 in glycerol and m/z 33 1, 332, and 333 in glucose) was performed on a Finnigan gas chromatograph/ mass spectrometer (model 3300).
Resolution of the glucose pentaacetate derivative was achieved using a 2 m x 2 mm glass column packed with 3% OV 101-mesh 100/200 packing material (Applied Sciences Laboratories, Inc., State College, PA). The column was maintained at 210 to 220°C during analysis, and isotopic enrichment was measured by analysis of the m/z 33 1 reflecting unlabeled glucose, the M + 1 ion cluster (m/z 332 reflecting '3C-glucose production from glycerol), and the M + 2 ion cluster (m/z 333 reflecting infused dideuterated glucose) after correcting for natural I3C and 2H abundance.
Resolution of the glycerol triacetate derivative was achieved using a 2 m x 2 mm glass column packed with 3% OV-17 Supelcoport (Supelco, Inc., Bellefonte, PA) and was maintained at 130°C. Isotopic enrichments were measured by GCMS analysis of the m/z 159 reflecting unlabeled glycerol, its corresponding M + 1 ion cluster (m/z 160 reflecting 13C-labeled glycerol), and M + 5 ion cluster (m/z 164 reflecting the deuterated internal standard), after making corrections for natural I3C abundance.
Rates of glucose production from glycerol were calculated from the single I3C contribution to the M + 1 ion (m/z 332) after appropriate corrections for natural isotopic contributions from unlabeled substrate and for 2H2-labeled glucose in the infusate, using standard curves of known isotopic content (15). Glucose concentrations were measured in each plasma sample using the conventional glucose oxidase method implemented on the Beckman Glucose Analyzer (Beckman Inc., Fullerton, CA).
Calculations. For the 2H21x0 doubly labeled water method, the zero-time intercepts of the plot of natural logarithmic enrichments of 'H and "0 ( y ) versus time post-dose ( x ) were used to calculate isotope elimination rates and isotope dilution spaces. Total body water was calculated from mean dilution spaces [i.e.
('H + "0)/2], assuming 2H overestimates body water by 4% and that "0 overestimates body water by 1% (17). Fat-free mass was estimated from the mean body water volume calculated from dilution of both isotopes for each subject, assuming the hydration coefficient of fat-free mass for infants 1 to 2 mo postnatally is 78.3% (22). Rates of C 0 2 production were calculated as described ( 16, 17). Oxygen consumption was calculated assuming a respiratory exchange ratio of 0.9 1, derived from published studies of growing preterm infants (23-26). Caloric equivalents of C 0 2 were calculated using Weir's equation (27) glucose (m/z 333133 I), respectively]. Glucose derived from glycerol was calculated from the 13C-glucose enrichments at 180 min. The average coefficients of variation of the individual subjects' plasma glycerol concentrations between 100 and 180 min were 5 -t 2% in theophylline-treated and 9 f 6% in control infants. These values were not statistically different and support attainment of substrate steady state during the period of kinetic analysis.
Statistical analysis. Data are presented as means f SD unless otherwise stated. Means and data from correlation analyses were compared using t tests. The Mann-Whitney test for differences between means was applied to the energy expenditure data because the data were highly skewed by one individual. An effect of caloric intake during the 7 d preceding the study on glycerol flux was tested using analysis of variance. Differences were considered significant at p < 0.05.
RESULTS

Clinical characteristics.
Selected clinical characteristics are shown in Table 1 . By Dubowitz score, the estimated gestational age at birth of the theophylline-treated infants (30 f 2 wk) was significantly younger than of the control infants (32 f 1 wk) ( p < 0.00 1). However, corrected gestational ages (estimated gestational age plus postnatal age) on study d 1 were comparable, averaging 36 If: 2 in theophylline-treated and 35 f 1 wk in control infants, respectively. Neither mean birth weight (1295 + 366 g versus 1547 f 210 g, respectively), mean body weight on d 1 of the study (1686 f 128 versus 1703 k 231 g, respectively) , nor body weight on the day of the infusion studies (1898 f 124 versus 1917 f 247 g, respectively) differed statistically. Body water ( Table 2 ) was 68.5 + 3.4% of body weight in the theophylline-treated infants and 70.2 If: 3.4% of body weight in the control infants ( p = NS). Based on an estimate of 78.3% hydration of the fat-free compartment in infants at 1 to 2 mo of postnatal life (22), the average fat percentage of body weight was estimated as 10% in theophylline-treated and 13% in control infants.
Mean plasma theophylline level in theophylline-treated infants was 8 f 1 pg/mL (range, 5-12 pg/mL, equivalent to 28-67 pM), which is within the therapeutic range. There was no clinical evidence of theophylline toxicity. Mean caloric intake during 7 d immediately before the study was not significantly different between groups (I 18 f 15 kcall kg/d in theophylline-treated infants and 134 + 2 1 kcal/kg/d in control infants), nor was caloric intake during the doubly labeled water study significantly different (121 + 11 versus 13 1 f 18 kcal/kg/d in the theophylline-treated infants and control infants, respectively).
CO2 production. Isotopic dilution spaces for 'H and 180, body water volumes, isotope elimination rates, rates of C 0 2 production, and energy expenditure data are listed in Table 2 . Ratios of isotope dilution spaces (2H/'80) calculated by the back-extrapolation method were 1.032 + 0.02 in theophylline-treated and 1.038 + 0.027 in control infants and were comparable to the ratio (1.025) that was calculated in the same way in preterm infants whose average daily weight gain was 15 g/kg/d (23). Paired comparisons of body water volumes measured by 'H-and '80-dilution showed no statistically significant difference in either the theophylline-treated ( p = 0.803) or control ( p = 0.554) infants. Mean rates of C 0 2 production were nearly identical in both groups, averaging 0.95 f 0.34 mol/d in theophylline-treated infants and 0.91 f 0.17 mol/d in control infants ( p = NS). Average daily energy expenditure was 65 f 22 kcallkg body weight and 59 + 5 kcallkg body weight in the respective groups ( p = NS by t test and Mann-Whitney comparisons because energy expenditure in one infant treated with theophylline was 127 kcal/kg/d, which was 2 to 3 SD beyond the mean, which skewed the energy expenditure data in the theophylline-treated infants). Mean + SD energy expenditure for theophylline-treated infants without the data from this particular infant was 57 + 7 kcal/kg/d (n = 6). Per kg of fat-free mass, daily energy expenditure was 65.5 + 5.6 kcal (n = 6) and 66.3 + 5.5 kcal in theophylline-treated infants and control infants, respectively, indicating that theophylline at therapeutic concentrations did not increase average daily energy expenditure. Further evidence for this is that individuals' plasma theophylline levels were not correlated with daily energy expenditure ( r = 0.102). (Table 3 ) was 4.16 + 0.50 mM (75 f 9 mg/dL) in theophylline-treated (mean coefficient of variation = 6%) and 4.06 f 0.56 mM (73 f 10 mg/dL) in controls (mean coefficient of variation = 5%), confirming normoglycemia and glucose steady state during the entire study.
Baseline plasma glycerol concentration was 107 + 30 pM in theophylline-treated infants, statistically less than the concentration in the controls, 17 1 f 36 pM ( p = 0.004). The basal plasma glycerol concentrations were within the range reported for newborn term and preterm infants (1 5) and for infants 1 to 6 mo of age (28) but were lower than concentrations reported recently in normal newborn term infants and lower than in newborn term infants of insulin-dependent diabetic mothers (29). The intersubject variability in glycerol concentration was not due to the length of time between the last feeding and the basal blood sample, inasmuch as the interval was comparable for all infants Table 3 . Concentrations and kinetics of glucose and glycerol 4 to 6 h after feeding In the one infant whose basal blood sample was drawn 85 rnin postprandially, plasma glycerol was 180 pM. The baseline glycerol concentration was also not a function of caloric intake in the feeding that preceded the baseline blood sample (18 f 5 kcal/kg; range, 14-26 kcal/kg). Plasma glycerol concentrations between 100 and 180 min from the start of the infusion, equivalent to 280 through 360 min from the last feeding (Table 3) , were 108 + 30 pM in theophyllinetreated infants and not statistically different from 143 f 45 pM in controls.
Glucose production. Glucose production (Table 3) Lipolysis. Four to 6 h after the last feeding, rates of glycerol flux, and thus of lipolysis, were 9.6 + 2.0 pmol/kg/min in theophylline-treated infants and not statistically different from 9.3 f 2.4 pmol/kg/min in controls (Table 3) . Plasma glycerol concentrations were linearly correlated with glycerol flux rates (Fig. 1) in the combined group of control and theophylline-treated preterm infants (r = 0.67; p < 0.01), a finding consistent with previous observations in term newborn infants (15, 3 1).
Gluconeogenesisfrom glycerol. Glycerol appearing in plasma between 100 and 180 min of the infusion study (4-6 h from the last feeding) was used principally to form new glucose. The percentage of plasma glycerol flux converted to glucose 6 h after a feeding was nearly identical in both groups, averaging 82 + 18% of glycerol turnover in theophylline-treated infants and 8 1 If: 22% in the controls. In the theophylline-treated and control infants combined, 82 + 19% of the plasma glycerol appearance produced was converted to glucose, which was not statistically different from the mean observed (73 + 18%) in five newborn infants at steady state (15) or from 87 a 16% in six normal newborn infants (29).
Gluconeogenesis from glycerol accounted for 9.6 + 2% of glucose production in theophylline-treated infants at steady state, and for 10.4 f 4% in controls ( p = NS). The percentage of glucose derived from glycerol is related directly to plasma glycerol flux rates (r = 0.67; p < 0.01) shown in Figure 2 .
DISCUSSION
This study demonstrates that energy expenditure and rates of lipolysis, glucose and glycerol turnover, and gluconeogenesis GLYCEROL FLUX (prnol -kg-' -mi"-') 2 . Gluconeogenesis from glycerol a n d glycerol flux rates measured between 4 a n d 6 h after a feeding i n preterm infants treated with theophylline (V) a n d control infants (0) (n = 14; r = 0.66; p < 0.01).
from glycerol are unaltered by therapeutic concentrations of theophylline in preterm infants. This finding is at variance with one reported recently by Peters et al. (5) , who found that rates of lipolysis were increased by theophylline in fasted healthy adults. The discrepancy may be due to the fact that the infants had been medicated with theophylline for an average of 34 d (range, 15-49 d), whereas the adults had no history of chronic theophylline exposure. This speculation is consistent with the facts that theophylline's lipolytic effect may be due to its inhibition of adenosine receptor binding and that adenosine receptor density may be increased by chronic theophylline exposure (32). If receptor density had been increased by chronic use in the preterm infants, then theophylline's adenosine antagonism and lipolytic effects may have been blunted, which could explain the variance with the adults.
Glucose production rates measured in the present study are faster than rates reported previously from this laboratory (15, 30). Because rates in the present study overlap the ranges measured in the previous studies and because the previously studied infants were studied at different corrected gestational ages, chronologic ages, and with use of different feeding regimens, we do not believe that these statistical differences reflect significant biologic differences.
The rate of glycerol appearance in the two groups of growing preterm infants in this study was 9 to 10 pmol/kg/min and is faster than rates reported in normal adults (5). The issue in newborn infants is not completely settled. Bougnkres et al. (1 5) reported rates of 4.4 f 1.2 pmol/kg/min in term newborn infants studied on d 1 of postnatal life. Pate1 and Kalhan (29) reported rates of 9.5 k 2 or 9.6 + 2 /*mol/kg/rnin in appropriate for gestational age newborn term infants and infants of insulindependent diabetic mothers, respectively, studied 7 to 9 h after a feeding. Given the differences in postnatal age between infants in the present study and those reported earlier from our laboratory (1 5), we cannot conclude confidently whether lipolytic rates differ between term and preterm infants or whether postnatal age changes these rates, consistent with the observations of Marcus et al. (33) , who found age-related differences in the lipolytic responses of term infants' adipocytes to thyrotropin and catecholamines. Given the rapid lipolytic rates, it is tempting to speculate that theophylline at therapeutic doses has no effect on lipolysis in preterm infants, because lipid mobilization was already maximally stimulated 6 h after feeding. When the data of the present study are combined with those of the two previously reported neonatal glycerol flux studies of Bougnkres et al. (15) and Patel and Kalhan (29), a significant (p < 0.00 1) relationship between glycerol flux and plasma glycerol concentrations is apparent.
Because diet is one important variable that might influence the demand for hydrolysis of adipose tissue lipid stores, we analyzed the effect of dietary intake on the results described. All infants were consuming more than 100 kcal/kg/d for 1 wk before the study. Caloric intake was not regulated by the protocol, apart from the fact that a minimum intake of 100 kcal/kg/d was one criterion for inclusion. Because they were also all gaining weight (mean 18, range 10-20 g/kg/d), dietary energy intake was at least adequate. Additionally, there was no relationship of lipolysis or gluconeogenesis from glycerol to dietary energy across the intake range in this study.
We have also shown that glycerol can be a significant source of gluconeogenic carbon in preterm infants, supplying 9 to 10% of hepatic glucose production 4 to 6 h after a feeding (Fig. 2) . The glucogenic contribution from glycerol in our preterm infants was less than the rate recently reported by Patel and Kalhan (29), who found glycerol contributed 20% of new glucose carbon in newborn term infants. Because the FFA generated from peripheral adipose tissue lipolysis are themselves crucial for maintaining an adequate gluconeogenic rate and because glycerol represented an important source of gluconeogenic carbon in these premature infants, our data confirm that an active lipolytic rate is important for maintaining normoglycemia in the preterm infants. Further, our data imply that lipid mobilization and gluconeogenesis may already be maximally stimulated in the preterm infant at this stage of development, potentially explaining the failure of theophylline to further augment these rates.
The dilution spaces of 2H and '*0 were comparable to those measured previously in preterm infants (23 (35), using classic indirect calorimetry, reported comparable rates of energy expenditure. In contrast, Grant and Denne (36) reported slightly lower mean daily energy expenditure rates of 52 kcal/kg/d in intermittently fed newborn preterm infants. Their infants were fed only about 80% of the caloric intake used in the present study, however, so some of the discrepancy in measured energy expenditure is due to differences in energy intake and some to postnatal age and maturation. We used a respiratory exchange ratio of 0.91, based on published data from growing preterm infants (23-26). The assumption that the same respiratory exchange ratio could be used for both groups of infants is supported by our finding that rates of lipolysis were not statistically different between the groups and, by the previous finding, that the respiratory exchange ratio of premature infants was not altered by plasma theophylline in the range used in the present study (1 3).
Our study compared preterm infants treated with theophylline for symptoms of apnea of prematurity with untreated controls. Because there is no apparent effect of therapeutic doses of theophylline on rates of lipolysis or energy expenditure in preterm infants with apnea, it is unlikely that therapeutic doses of theophylline are responsible for growth failure in preterm infants with lung disease.
